Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis

References

• Cole P, Rabasseda X. The soluble tumor necrosis factor receptor etanercept. Drugs Today. 2004;40:281–324.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleisch-mann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.
   Google Scholar
• van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:3928–39.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a com-bination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.
   Google Scholar
• Emery P, Kvlein TK, Combe B, Foehl J, Pobertson D, Pedersen R, et al. Very early (4 months) treatment with combination etanercept and methotrexate produces significantly better remis-sion rates: results from the COMET study. Ann Rheum Dis. 2010;69(Suppl 3):57–8.
   Google Scholar
• Koike T, Harigai M, Inokuma A, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology pre-liminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• PMDA. New drug application and complete response letter of etanercept (53039601_21700AMY). http://www.info.pmda.go.jp/ approvalSrch/ApprovalSrch.
   Google Scholar
• Botsios C, Furlan A, Ostuni P, Striso P, Todesco S, Punzi L. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheu-matoid arthritis. Ann Rheum Dis. 2007;66(Suppl II):54.
   Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA,van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trial in rheumatoid arthritis: guidelines from a roundtable dis-cussion. Arthritis Rheum. 2002;47:215–8.
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.
   Google Scholar
• Schoonjans F, Zalata A, Depuydt CE, Comhaire FH. MedCale: a new computer program for medical statistics. Comput Methods Programs Biomed. 1995;48:257–62.
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, Koevoets R, van der Heijde DMFM, Gerards ten Wolde S, Kerstens PJSM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011. ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011;2011(70):1815–21.
   Google Scholar
• Inoue E, Yamanaka H, Hara M, Tomotsu T, Komatani N. Comparison of disease activity score (DAS)28-erythrocyte sedi-mentation rate and DA528-C-reactive protein threshold values. Ann Rheum Dis. 2007;66: 407–9.
   Google Scholar
• Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003; CD004525.
   Google Scholar
• Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
   PubMed Web of Science ®Google Scholar
• Keystone C, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–96.
   PubMed Web of Science ®Google Scholar
• Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory disease. Curr Opin Pharmacol. 2010;10:308–15.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary 0, Chosidow 0, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tubercu-losis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO regis-try. Ann Rheum Dis. 2010 (Epub ahead of print).
   Google Scholar
• Crum NF, Lederman ER, Wallace NR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine. 2005;84: 291–302.
   Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentra-tions in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–6.
   PubMed Web of Science ®Google Scholar
• Klareskog L, Wajdula J, Yeh P, Fatenej ad S. Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes following 5 years of treatment with Enbrel in patients with rheumatoid arthritis. Arthritis Rheum. 2005;52\(Suppl 9): S348.
   Google Scholar
• Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of eta-nercept liquid administered once weekly in patients with rheu-matoid arthritis. Clin Exp Rheumatol. 2007;25(1):40–6.
   PubMed Web of Science ®Google Scholar
• Hetland RF, Christensen U, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rate, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. Arthritis Rheum. 2010;62:22–32.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Wells GA, Zhang B, van Tuyl LHD, Funovits J, Boers M. Predictive validity of the new preliminary ACR/EU-LAR definitions for remission in rheumatoid arthritis. Arthritis Rheum. 2010;62(Suppl):5882.
   Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86.
   PubMed Web of Science ®Google Scholar